

Frailty Ascertainment:

Beginning of the pathway to treatment

Karen Bandeen-Roche, Ph.D.

Johns Hopkins
Older Americans Independence Center

Introduction

Whither “frailty ascertainment”?

- “Geronmetrics”
 - a.k.a.: econometrics, psychometrics, biometrics
 - Goal: Accurate and precise measurement of complex health states or spectra
- Rigorous measurement is essential to
 - Sensitivity, specificity for genetic, other discovery
 - Theory operationalization, testing
 - Correctly targeted, evaluated interventions
- Worth measuring as stand-alone construct?
 - If not, pursuing items under the last bullet makes little sense

Introduction

Gerontometric Measurement

- Proposition: Most effective when attacked “from both ends”
 - Mechanisms / basic science
 - Phenotype / validity
 - Face : Sensible?
 - Content : Captures all aspects?
Excludes extraneous aspects?
 - Criterion : Predicts relevant outcomes?
 - Construct : Captures assessment target?

This module aims to...

- Present theory identifying frailty
- Propose a frailty validation methodology
- Present measurement validation results
- Highlight areas of promise for future work

Theory: Frailty

Prevailing perspectives

- Obsolete: frailty = disability; disease
- **Rockwood et al**: accumulation of deficits; proximity to death
- **Lipsitz**: Loss of dynamical complexity
- **Studenski**: Geriatrician consensus
- **Deeg**: Static versus dynamic frailty— aggregate markers vs. changes


References 6; 24-26

Theory: Frailty...

- Is recognizable to (some?) geriatricians
- Has adverse geriatric consequences
- An **outcome of dysregulation** in multiple physiological systems
 - Inflammatory? Hormonal? Nutritional? Etc.?
- Is a **syndrome** of decreased resiliency and reserves manifesting in multiple domains
 - e.g., see next slide
- Is **distinct** from disease or disability

References 1-17

The Syndromic Cycle Theory



3-Fried et al., *J Gerontol* 56:M146-56; Bandeen-Roche et al., *J Gerontol*, 2006

Frailty Measurement Validation Methodology

- Criterion validity: “Frailty” = combination of aspects which well predicts adverse outcomes, or is well predicted by hypothesized risk factors
- Methods: Standard regression models (here); also neural nets, regression trees, logic regression, etc.

Frailty Measurement Validation Methodology


- Content validity: Science — Clarity in **construct definition**
 - Arguably: Key source of current debate
- Construct validity: **Theory testing**
 - Proposal: Latent (“underlying”) variable modeling — panels to follow
- Not a focus of this module, but worth keeping in mind: reliability of measures

Frailty Construct Validation

Latent Variable Methodology

- Views frailty as underlying; inferred through surrogates
- Then interest is in
 - **Measurement:** How does underlying frailty relate to measured criteria?
 - **Structure:** Relation of frailty to putative etiology or consequences

Frailty Construct Validation Latent Variable Methodology



Syndrome Validation Methods


- Internal convergent validity
- Criteria **manifestation is syndromic**

“a group of signs and symptoms that occur together and characterize a particular abnormality”¹⁸

–Method: **Latent class analysis^{19,27}**

Syndrome validation

Method: Latent class analysis



Syndrome validation

Method: Latent class analysis

- Seeks clinically homogeneous subgroups
- Features that characterize latent groups
 - Prevalence in overall population
 - Percentage manifesting each criterion
- If criteria characterize syndrome:
 - At least two groups (otherwise, no co-occurrence)
 - No subgrouping of symptoms (otherwise, more than one abnormality characterized)

Frailty Construct Validation Method Philosophy

- Role of latent variable modeling?
 - ~~Reveal underlying truth?~~
 - Operationalize and test theory
 - Convergent and discriminant
 - Sensitivity analyses
 - Do minor changes to theory greatly affect conclusions?

Methods

Data: Women's Health & Aging Studies²⁰⁻²¹

- Fried et al. (2001)³ measures: 5 criteria
 - Robust = none; Intermediate=1-2; Frail=3 or more

Frailty-defining criteria: WHAS

Criterion	Definition	%
1. Weight loss	Either of: i) Weight at age 60–weight at exam \geq 10% of age 60 weight.; ii) BMI at exam $<$ 18.5.	12.7
2. Exhaustion	Self report of any of: i) low usual energy level (\leq 3, range 0-10); felt unusually (ii) tired (iii) weak in last month	14.1
3. Low Energy Expenditure	90 on activity scale (6 items)	19.8
4. Slowness	walking 4m: speed \leq 4.57/7 for height \leq 159 cm; speed \leq 4.57/6 for height $>$ 159 cm	31.3
5. Weakness	Grip strength: \leq 17 for BMI \leq 23; \leq 17.3 for BMI 23.1 - 26 \leq 18 for BMI 26.1 – 29; \leq 21 for BMI $>$ 29As for CHS.	20.8
OVERALL FRAILTY STATUS	Robust	44.9
	Intermediate	43.8
	Frail	11.3

Results

Face Validity

- Face validity
 - Criteria reflect geriatric impression
 - WHAS I: prevalence increases with age
 - WHAS: prevalence higher among more disabled (25.4%) than overall (11.3%)
- Cross validity
 - Prevalence similar across cohorts (11.3% in WHAS; 11.6% in age-matched CHS women)

Results

Criterion Validity

Association of Baseline Frailty Status and Risk of Incident Adverse Events,
Combined WHAS I (rounds 1, 4, 7) and WHAS II (rounds 1, 2, 3) Cohorts (n=784)

Outcome	Adjusted Hazard Ratios (95% Confidence Intervals)	
	Intermediate	Frail
Fall (n=560)	0.92 (0.63, 1.34)	1.18 (0.63, 2.19)
Severe ADL Disability (n=612)	5.68 (2.41, 13.42)	15.79 (5.83, 42.78)
Severe IADL Disability (n=698)	3.53 (1.20, 10.35)	10.44 (3.51, 31.00)
Hospitalization (n=715)	0.99 (0.67, 1.47)	0.67 (0.33, 1.35)
Permanent Nursing Home Entry (n=750)	5.16 (0.81, 32.79)	23.98 (4.45, 129.2)
Death (n=766)	3.50 (1.91, 6.39)	6.03 (3.00, 12.08)

- Phenotype strongly predicts adverse outcomes
- Phenotype predicted by signs of systemic dysregulation: inflammatory, immunological, hormonal, nutritional

Conditional Probabilities of Meeting Criteria in Latent Frailty Classes WHAS

Criterion	2-Class Model		3-Class Model		
	CL. 1 NON- FRAIL	CL. 2 FRAIL	CL. 1 ROBUST	CL. 2 INTERMED.	CL. 3 FRAIL
Weight Loss	.073	.26	.072	.11	.54
Weakness	.088	.51	.029	.26	.77
Slowness	.15	.70	.004	.45	.85
Low Physical Activity	.078	.51	.000	.28	.70
Exhaustion	.061	.34	.027	.16	.56
Class Prevalence (%)	73.3	26.7	39.2	53.6	7.2

Bandein-Roche et al., 2006

Results

Syndrome Validation

- Two class model fit is good
 - Pearson χ^2 p-value=.22; minimized Akaike²² & Bayesian²³ Information Criteria
- In three-class model: mean # of criteria in “intermediate,” “frail” groups = 1.26, 3.42—in line with defined cutoffs
- Frailty criteria prevalence stepwise across classes—no subclustering
- Syndromic manifestation well indicated

Measurement of Frailty

Discussion: Areas of Promise

- Content validity: All aspects covered?
 - Cognitive decline?
 - Depression / anxiety?
 - **Physiotype** rather than phenotype?
- Construct validity
 - External validity
 - Link to **multisystemic** dysregulation
 - Specificity re **vulnerability to stressors**
 - Discriminant: What is frailty **not**?

Discriminant Validity

More than Component Parts

- WHAS: Disease-adjusted analysis, mobility disability vs. components
 - Slowness=strongest predictor
OR=17, 95% CI [7.8, 38] vs.
6.6, 95% CI [2.2, 20] for weakness
 - All but weight loss predict (multiply)

Discriminant Validity Data

More than disease, disability (WHAS)

- Frail, # diseases associated, not redundant
 - “Frail” rare if no (2%) or 1 (5%) disease
 - “Intermediate” not rare these cases (>29%)
 - Many with comorbid diseases robust (>28%)
- Frailty strongly predicts mobility disability, independently of age, # diseases
 - OR for severe disability = 29 (95% CI [9.3,88])
 - Little interaction w disease: not severity marker

Discriminant Validity Data

More than disease (WHAS)

- Mortality analysis with propensity scoring

ADJUSTMENT	FRAILTY OR (CI)
None	2.42 (1.81,3.24)
Disease count, age	1.81 (1.33,2.45)
Cluster-based C/D/S vars.	1.74 (1.28,2.36)
Elements of score	1.69 (1.23,2.30)
Propensity score	1.67 (1.22,2.28)
P. Score: Mid-90	1.51 (1.07,2.13)

Frailty Ascertainment

Discussion: Areas of Promise

- Criterion validity
 - ...i.e. utility for **screening, diagnosing & targeting** adverse geriatric outcomes
 - Needed
 - Delineation of predictive accuracy
 - Reliability delineation and refinement
 - Comparison among competitors
 - Threshold relationships?

Frailty Ascertainment: Summary

- Rigorous frailty ascertainment is essential to treatment development!
- A key element of rigor: validity
 - Does ascertainment “hit the target”?
 - Target: involves theory
- Working theory:

*Frailty is a free-standing **syndrome** of decreased resiliency and reserves that results from dysregulation in multiple physiological systems and **has adverse geriatric consequences***

- Evidence presented re Fried et al. (2001) phenotype:

Face, criterion, and construct validity for syndrome with adverse consequences

Acknowledgments

- Funding / Institutional Support
Johns Hopkins Older Americans Independence Center,
National Institute on Aging, Brookdale National
Foundation
- References: See attached
- Basis:

PHENOTYPE OF FRAILITY:
CHARACTERIZATION IN THE WOMEN'S
HEALTH AND AGING STUDIES

J Gerontol Med Sci, 2006